Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Fludarabine Phosphate in Acute Myeloid Leukemia: NCT06904066 Clinical Landscape Report 2026
16 October 2026
NCT06904066 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lebrikizumab in Dermatitis, Atopic: NCT06906497 Clinical Landscape Report 2026
16 October 2026
NCT06906497 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19&CD22 bispecific CAR-T Cells(Hebei Taihe Chunyu Biotechnology) in Acute Myeloid Leukemia: NCT06911710 Clinical Landscape Report 2026
16 October 2026
NCT06911710 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
WD-890 in Plaque psoriasis: NCT06912165 Clinical Landscape Report 2026
16 October 2026
NCT06912165 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA CAR-T Cell(Xuzhou Medical University) in Multiple Myeloma: NCT06913192 Clinical Landscape Report 2026
16 October 2026
NCT06913192 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Olaparib in Primary peritoneal carcinoma: NCT06915025 Clinical Landscape Report 2026
16 October 2026
NCT06915025 clinical landscape for Primary peritoneal carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT06910124 Clinical Landscape Report 2026
16 October 2026
NCT06910124 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Letermovir in Multiple Myeloma: NCT06920251 Clinical Landscape Report 2026
16 October 2026
NCT06920251 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
RSS0393 in Chronic large plaque psoriasis: NCT06918743 Clinical Landscape Report 2026
16 October 2026
NCT06918743 clinical landscape for Chronic large plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Lenalidomide in Multiple Myeloma: NCT06918002 Clinical Landscape Report 2026
16 October 2026
NCT06918002 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Core binding factor acute myeloid leukemia: NCT06917911 Clinical Landscape Report 2026
16 October 2026
NCT06917911 clinical landscape for Core binding factor acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development…
9 min read
Apremilast in Psoriasis vulgaris: CTRI/2025/04/084479 Clinical Landscape Report 2026
16 October 2026
CTRI/2025/04/084479 clinical landscape for Psoriasis vulgaris: endpoints, sponsor, phase, geography, readouts, asset context and development white space.